Website
News25/Ratings3
News · 26 weeks59+163%
2025-10-262026-04-19
Mix3490d
- SEC Filings11(32%)
- Insider7(21%)
- Other5(15%)
- Leadership5(15%)
- Dividends4(12%)
- Analyst1(3%)
- Other1(3%)
Latest news
25 items- PRPlus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announced today the initiation of manufacturing activities and technology transfer with SpectronRx under a previously executed Master Services Agreement (MSA), in support of late-stage clinical manufacturing of Rhenium-186 and REYOBIQ. With SpectronRx serving as a second GMP manufacturing site alongside Radiomedix, and Rhenium-186 isotope supplied through Telix Pharmaceuticals, Plus strengthens the reliability of its multi-partner supply chain
- INSIDERSEC Form 4 filed by Daniels Eric Joseph4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- PRPlus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)HOUSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that it has granted inducement awards to Eric J Daniels, M.D., its new Chief Development Officer who joined the Company on April 20, 2026. The awards were granted on April 20, 2026 under the Company's 2015 New Employee Incentive Plan, as amended, which provides for the granting of equity awards to new employees as an inducement to join the Company. The inducement awards consist of options to purchase 20,000 shares of the Company common
- INSIDERSEC Form 3 filed by new insider Daniels Eric Joseph3 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- SECPLUS THERAPEUTICS Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
- PRPlus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementHOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Nasdaq determined that, for the 10 consecutive business days from April 6, 2026 to April 17, 2026, the closing bid price of the Company's common stock was at or above $1.00 per share. Accordingly, Nasdaq has advised that the matter
- PRPlus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial ExecutionHOUSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the appointment of Randy H. Goodman, Ph.D., M.H.A., as Vice President, Value Strategy & Health Economics and Outcomes Research (HEOR), effective April 13th, 2026. Dr. Goodman is a highly experienced health economics and market access leader with more than 20 years of experience spanning global pricing and reimbursement strategy, real-world evidence generation, and value-based healthcare modeling across the biotechnology, pharmaceutic
- SECPLUS THERAPEUTICS Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
- PRPlus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical PipelineHOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the appointment of Eric J. Daniels, M.D., MBA, as Chief Development Officer, effective April 20, 2026. Dr. Daniels is a seasoned biotechnology executive with more than two decades of experience spanning clinical development, regulatory strategy, corporate operations, and business development. He most recently served as Chief Development Officer at Kiora Pharmaceuticals , where he oversaw the company's full development portfolio
- SECPLUS THERAPEUTICS Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
- PRPlus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant GliomasHOUSTON, April 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to REYOBIQ™ (rhenium Re186 obisbemeda) for the treatment of pediatric malignant gliomas. Pediatric malignant gliomas are rare, aggressive brain tumors with limited treatment options and poor outcomes, where current standards of care—including surgery and radiation—often fail to prevent recurrence. Notably, the FDA granted orphan de
- PRPlus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial AdoptionHOUSTON, April 07, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that the American Medical Association (AMA) has approved a new, Proprietary Laboratory Analyses (PLA) Current Procedural Terminology (CPT) code for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) test. The dedicated billing code, 0640U, effective July 1, 2026, establishes a unique reimbursement identifier for the CNSide CSF TCE test, supporting payer claims processing and facilitating broader clinical adoptio
- SECPLUS THERAPEUTICS Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
- PRPlus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered LivesHOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), today announces a new payer coverage agreement with Highmark, effective April 1, 2026, providing reimbursement for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay for patients with metastatic central nervous system cancers. Highmark joins a growing list of national and regional payers, including United Healthcare and Humana, that provide coverage for CNSide. The addition of Highmark expands CNSide's total covered lives from approximately 67 million to 75 million, representing continued progress toward t
- INSIDERSEC Form 4 filed by Hedrick Marc H4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERSEC Form 4 filed by Sims Andrew John Hugh Macintyre4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- SECSEC Form DEFA14A filed by PLUS THERAPEUTICS Inc.DEFA14A - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
- PRPlus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced that it has granted inducement awards to two new employees who recently joined the Company. The awards were granted on March 26, 2026 under the Company's 2015 New Employee Incentive Plan, as amended, which provides for the granting of equity awards to new employees as an inducement to join the Company. The inducement awards consist in the aggregate of options to purchase 300,000 shares of Company common stock and 300,000 restricted stoc
- SECSEC Form DEF 14A filed by PLUS THERAPEUTICS Inc.DEF 14A - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
- PRPlus Therapeutics Announces Reverse Stock SplitHOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-25. The reverse stock split will become effective at 12:01 a.m. Eastern Time on April 2, 2026, and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on April 2, 2026 under the Company's existing trading symbol, "PSTV." At such time, the Company's common stock will also comm
- INSIDERSEC Form 3 filed by new insider Andrews Ronald Asbury3 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- SECPLUS THERAPEUTICS Inc. filed SEC Form 8-K: Leadership Update8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
- PRPlus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of DirectorsHOUSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the appointment of diagnostics industry veteran Ron Andrews to its Board of Directors. "Ron Andrews brings an extensive wealth of diagnostics experience to the Plus board room developed over multiple decades in the industry," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "He will make an immediate impact on the Company as we scale CNSide, first in the U.S. and then globally. Furthermore, his bre
- PRPlus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the presentation of a new health economics study evaluating the economic impact of earlier detection and therapeutic management of LM using the CNSide cerebrospinal fluid (CSF) assay. The cost-of-care analysis suggests that earlier LM diagnosis and therapeutic management enabled by CNSide may reduce overall LM-related healthcare costs by approximately 40%, primarily through earlier therapeutic intervention, improved treatment precisio
- SECPLUS THERAPEUTICS Inc. filed SEC Form 8-K: Shareholder Director Nominations, Other Events8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)